Sandoz Subsidiary Opens Biopharma Facility in Slovenia

Lek (Ljubljana, Slovenia), a Sandoz subsidiary, says it has opened a new facility for the production of biopharmaceutical active substances at Mengeš, Slovenia. The new facility, which involved an investment of about $3.75 million, will serve as a global supply point for Sandoz modified proteins. The Mengeš site is one of the three main biopharmaceutical development and production centers for Sandoz, a division of Novartis, and also a center for cell culture and modified protein technology. “Biologics are an increasingly indispensable part of...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers